.Pharmacolibrary.Drugs.ATC.N.N03AX14_1 .Pharmacolibrary.Drugs.ATC.N.N03AX14_1| name: | Levetiracetam_1 |
| ATC code: | N03AX14_1 | route: | intravenous |
| n-compartments | 1 |
Levetiracetam is an anticonvulsant medication used primarily for the treatment of epilepsy. It is indicated as adjunctive therapy for partial onset seizures, myoclonic seizures, and tonic-clonic seizures in adults and children. Levetiracetam is widely approved and used in clinical practice today.
Pharmacokinetic parameters reported in healthy adult subjects after intravenous administration.
Ong, CLJ, et al., & Kwa, LHA (2021). Pharmacokinetics of levetiracetam in neurosurgical ICU patients. Journal of critical care 64 255–261. DOI:10.1016/j.jcrc.2021.04.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34051579
Klein, P, & Bourikas, D (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. Advances in therapy 41(7) 2682–2699. DOI:10.1007/s12325-024-02876-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/38811492
Toublanc, N, et al., & Andreas, JO (2015). Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration. European journal of drug metabolism and pharmacokinetics 40(4) 461–469. DOI:10.1007/s13318-014-0227-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25283522